logo-loader
viewSeelos Therapeutics

Seelos Therapeutics to meet with FDA on its proof-of-concept ketamine study to treat depression

Seelos Therapeutics Inc (NASDAQ:SEEL) CEO Raj Mehra tells Proactive Investors the New York-based biopharma is scheduled to meet with the FDA to design a proof-of-concept study linked to its intranasal ketamine depression treatment aimed at patients with post-traumatic stress disorder (PTSD) at imminent risk of suicide.

Dr Mehra also commented on the positives from President Donald Trump's recent announcement that he would he would be willing to help the Department of Veteran Affairs with negotiating the price of a new Johnson & Johnson (NYSE:JNJ) ketamine depression drug.

Quick facts: Seelos Therapeutics

Price: 0.8845 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $23.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read